Transjugular intrahepatic collateral-systemic shunt is effective for cavernous transformation of the portal vein with variceal bleeding.


Journal

Hepatology international
ISSN: 1936-0541
Titre abrégé: Hepatol Int
Pays: United States
ID NLM: 101304009

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 17 11 2022
accepted: 13 03 2023
medline: 31 7 2023
pubmed: 25 4 2023
entrez: 25 4 2023
Statut: ppublish

Résumé

The transjugular intrahepatic portal collateral-systemic shunt (transcollateral TIPS) is used to treat portal hypertension-related complications in patients with cavernous transformation of the portal vein (CTPV) and whose main portal vein cannot be recanalized. It is still not clear whether transcollateral TIPS can be as effective as portal vein recanalization-transjugular intrahepatic portosystemic shunt (PVR-TIPS). This study aimed to evaluate the efficacy and safety of transcollateral TIPS in the treatment of refractory variceal bleeding with CTPV. Patients with refractory variceal bleeding caused by CTPV were selected from the database of consecutive patients treated with TIPS in Xijing Hospital from January 2015 to March 2022. They were divided into the transcollateral TIPS group and the PVR-TIPS group. The rebleeding rate, overall survival, shunt dysfunction, overt hepatic encephalopathy (OHE) and operation-related complications were analyzed. A total of 192 patients were enrolled, including 21 patients with transcollateral TIPS and 171 patients with PVR-TIPS. Compared with the patients with PVR-TIPS, the patients with transcollateral TIPS had more noncirrhosis (52.4 vs. 19.9%, p = 0.002), underwent fewer splenectomies (14.3 vs. 40.9%, p = 0.018), and had more extensive thromboses (38.1 vs. 15.2%, p = 0.026). There were no differences in rebleeding, survival, shunt dysfunction, or operation-related complication rates between the transcollateral TIPS and PVR-TIPS groups. However, the OHE rate was significantly lower in the transcollateral TIPS group (9.5 vs. 35.1%, p = 0.018). Transcollateral TIPS is an effective treatment for CTPV with refractory variceal bleeding.

Sections du résumé

BACKGROUND BACKGROUND
The transjugular intrahepatic portal collateral-systemic shunt (transcollateral TIPS) is used to treat portal hypertension-related complications in patients with cavernous transformation of the portal vein (CTPV) and whose main portal vein cannot be recanalized. It is still not clear whether transcollateral TIPS can be as effective as portal vein recanalization-transjugular intrahepatic portosystemic shunt (PVR-TIPS). This study aimed to evaluate the efficacy and safety of transcollateral TIPS in the treatment of refractory variceal bleeding with CTPV.
METHODS METHODS
Patients with refractory variceal bleeding caused by CTPV were selected from the database of consecutive patients treated with TIPS in Xijing Hospital from January 2015 to March 2022. They were divided into the transcollateral TIPS group and the PVR-TIPS group. The rebleeding rate, overall survival, shunt dysfunction, overt hepatic encephalopathy (OHE) and operation-related complications were analyzed.
RESULTS RESULTS
A total of 192 patients were enrolled, including 21 patients with transcollateral TIPS and 171 patients with PVR-TIPS. Compared with the patients with PVR-TIPS, the patients with transcollateral TIPS had more noncirrhosis (52.4 vs. 19.9%, p = 0.002), underwent fewer splenectomies (14.3 vs. 40.9%, p = 0.018), and had more extensive thromboses (38.1 vs. 15.2%, p = 0.026). There were no differences in rebleeding, survival, shunt dysfunction, or operation-related complication rates between the transcollateral TIPS and PVR-TIPS groups. However, the OHE rate was significantly lower in the transcollateral TIPS group (9.5 vs. 35.1%, p = 0.018).
CONCLUSION CONCLUSIONS
Transcollateral TIPS is an effective treatment for CTPV with refractory variceal bleeding.

Identifiants

pubmed: 37097537
doi: 10.1007/s12072-023-10522-z
pii: 10.1007/s12072-023-10522-z
pmc: PMC10386942
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

979-988

Informations de copyright

© 2023. The Author(s).

Références

Senzolo M, Garcia-Tsao G, Garcia-Pagan JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol. 2021;75(2):442–453
doi: 10.1016/j.jhep.2021.04.029 pubmed: 33930474
Senzolo M, Teresa MS, Rossetto V, Burra P, Cillo U, Boccagni P, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int. 2012;32(6):919–27
doi: 10.1111/j.1478-3231.2012.02785.x pubmed: 22435854
Knight GM, Clark J, Boike JR, Maddur H, Ganger DR, Talwar A, et al. TIPS for adults without cirrhosis with chronic mesenteric venous thrombosis and EHPVO refractory to standard-of-care therapy. Hepatology. 2021;74(5):2735–2744
doi: 10.1002/hep.31915 pubmed: 34021505
Salem R, Vouche M, Baker T, Herrero JI, Caicedo JC, Fryer J, et al. Pretransplant portal vein recanalization-transjugular intrahepatic portosystemic shunt in patients with complete obliterative portal vein thrombosis. Transplantation. 2015;99(11):2347–2355
doi: 10.1097/TP.0000000000000729 pubmed: 25905983
Kallini JR, Gabr A, Kulik L, Ganger D, Lewandowski R, Thornburg B, et al. Noncirrhotic complete obliterative portal vein thrombosis: novel management using trans-splenic transjugular intrahepatic portosystemic shunt with portal vein recanalization. Hepatology. 2016;63(4):1387–1390
doi: 10.1002/hep.28429 pubmed: 26709234
Habib A, Desai K, Hickey R, Thornburg B, Vouche M, Vogelzang RL, et al. Portal vein recanalization-transjugularintrahepatic portosystemic shunt using the transsplenic approach to achieve transplant candidacy in patients with chronic portal vein thrombosis. J Vasc Interv Radiol. 2015;26(4):499–506
doi: 10.1016/j.jvir.2014.12.012 pubmed: 25666626
Thornburg B, Desai K, Hickey R, Kulik L, Ganger D, Baker T, et al. Portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: technical considerations. Tech Vasc Interv Radiol. 2016;19(1):52–60
doi: 10.1053/j.tvir.2016.01.006 pubmed: 26997089
European Association for the Study of the Liver. Electronic address EEE. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016;64(1):179–202
Tripathi D, Stanley AJ, Hayes PC, Travis S, Armstrong MJ, Tsochatzis EA, et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut. 2020;69(7):1173–1192
doi: 10.1136/gutjnl-2019-320221 pubmed: 32114503
Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;73(1):366–413
doi: 10.1002/hep.31646 pubmed: 33219529
Hepatobiliary Disease Study Group CSoGCMA. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai). J Dig Dis. 2021;22(4):176–186
doi: 10.1111/1751-2980.12970
Perarnau JM, Baju A, D’Alteroche L, Viguier J, Ayoub J. Feasibility and long-term evolution of TIPS in cirrhotic patients with portal thrombosis. Eur J Gastroenterol Hepatol. 2010;22(9):1093–1098
doi: 10.1097/MEG.0b013e328338d995 pubmed: 20308910
Zhang JB, Chen J, Zhou J, Wang XM, Chen S, Chu JG, et al. Systematic review and meta-analysis of trans-jugular intrahepatic portosystemic shunt for cirrhotic patients with portal vein thrombosis. World J Clin Cases. 2021;9(19):5179–5190
doi: 10.12998/wjcc.v9.i19.5179 pubmed: 34307565 pmcid: 8283597
Fanelli F, Angeloni S, Salvatori FM, Marzano C, Boatta E, Merli M, et al. Transjugular intrahepatic portosystemic shunt with expanded-polytetrafuoroethylene-covered stents in non-cirrhotic patients with portal cavernoma. Dig Liver Dis. 2011;43(1):78–84
doi: 10.1016/j.dld.2010.06.001 pubmed: 20637712
Han G, Qi X, He C, Yin Z, Wang J, Xia J, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol. 2011;54(1):78–88
doi: 10.1016/j.jhep.2010.06.029 pubmed: 20932597
Yamagami T, Nakamura T, Tanaka O, Akada W, Takayama T, Maeda T. Transjugular intrahepatic portosystemic shunt after complete obstruction of portal vein. J Vasc Interv Radiol. 1999;10(5):575–578
doi: 10.1016/S1051-0443(99)70086-2 pubmed: 10357483
Brountzos EN, Malagari K, Alexopoulou E, Nikolaou VE, Panagiotou I, Argyriou P, et al. Transjugular intrahepatic portosystemic shunt in cavernomatous portal vein occlusion. Hepatogastroenterology. 2004;51(58):1168–1171
pubmed: 15239270
de Franchis R, Baveno VF. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53(4):762–768
doi: 10.1016/j.jhep.2010.06.004 pubmed: 20638742
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VIIF. Baveno VII—renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–974
doi: 10.1016/j.jhep.2021.12.022 pubmed: 35120736
European Association for the Study of the Liver. Electronic address EEE and European Association for the Study of the L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69(2):406–460
Dell’Era A, Iannuzzi F, Fabris FM, Fontana P, Reati R, Grillo P, et al. Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation. Dig Liver Dis. 2014;46(2):152–156
doi: 10.1016/j.dld.2013.08.138 pubmed: 24084343
Lv Y, Qi X, He C, Wang Z, Yin Z, Niu J, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut. 2018;67(12):2156–2168
doi: 10.1136/gutjnl-2017-314634 pubmed: 28970291
Wils A, van der Linden E, van Hoek B, Pattynama PM. Transjugular intrahepatic portosystemic shunt in patients with chronic portal vein occlusion and cavernous transformation. J Clin Gastroenterol. 2009;43(10):982–984
doi: 10.1097/MCG.0b013e31819706a4 pubmed: 19417681

Auteurs

Jun Tie (J)

National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi'an, 710032, Shaanxi, China. tiejun7776@163.com.

Xiaoyuan Gou (X)

National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi'an, 710032, Shaanxi, China.

Chuangye He (C)

National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi'an, 710032, Shaanxi, China.

Kai Li (K)

National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi'an, 710032, Shaanxi, China.

Xulong Yuan (X)

National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi'an, 710032, Shaanxi, China.

Wenyuan Jia (W)

National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi'an, 710032, Shaanxi, China.

Jing Niu (J)

National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi'an, 710032, Shaanxi, China.

Na Han (N)

National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi'an, 710032, Shaanxi, China.

Jiao Xu (J)

National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi'an, 710032, Shaanxi, China.

Ying Zhu (Y)

National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi'an, 710032, Shaanxi, China.

Wenlan Wang (W)

Department of Aerospace Hygiene, School of Aerospace Medicine, Air Force Medical University, Xi'an, 710032, Shaanxi, China. ypwl821@fmmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH